<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634319</url>
  </required_header>
  <id_info>
    <org_study_id>4004‐22</org_study_id>
    <nct_id>NCT03634319</nct_id>
  </id_info>
  <brief_title>Early Evaluation of the Beacon Aqueous Microshunt in Patients Refractory to Drug Therapy in the European Union</brief_title>
  <acronym>EARLY BIRD EU</acronym>
  <official_title>Early Evaluation of the Brown Glaucoma Implant in Patients Refractory to Drug Therapy in the European Union</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroOptx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MicroOptx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective, non-randomized, single-arm study to assess the safety and effectiveness
      of lowering intraocular pressure with the Beacon Aqueous Microshunt. A total of 65 subjects
      will be enrolled at five centers. The primary endpoint will be assessed at 12 month
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.
Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in IOP</measure>
    <time_frame>12 Months</time_frame>
    <description>Overall responder rate, with responder defined as a subject with a diurnal intra‐ocular pressure equal to or lower than the individually pre-determined target IOP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Event Rate</measure>
    <time_frame>12 Months</time_frame>
    <description>Rate of all AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in IOP</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in IOP at follow-up compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate for 20% reduction</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as a subject achieving at least 20% reduction from baseline in IOP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in IOP lowering medication</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in number of medications at follow-up compared to baseline</description>
  </secondary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Beacon Aqueous Microshunt</intervention_name>
    <description>The Beacon Aqueous Microshunt is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.
Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 22 years and older.

          2. Diagnosed with mild, moderate or severe open‐angle glaucoma (OAG).

          3. Any IOP‐lowering medications should be stabilized at least 30 days prior to baseline
             measurements.

          4. Able and willing to comply with protocol requirements.

          5. Able to understand and sign the Informed Consent form.

        Exclusion Criteria:

          1. Active Neovascular Glaucoma in the study eye.

          2. Corneal conditions in the study eye that may inhibit normal incisional healing (e.g.
             Fuch's dystrophy) or impair visualization of the implant inside the anterior chamber.

          3. Anticipated need for ocular surgery within one year in the study eye.

          4. Contact lens use in the study eye.

          5. Clinically significant inflammation or infection in the study eye within 60 days prior
             to the preoperative visit

          6. Patients who have undergone surgery in the trial eye within the last 6 months. Note
             that planned simultaneous cataract surgery is not an exclusion criterion

          7. Angle closure glaucoma

        If both eyes of a prospective trial participant are eligible, the eye with the highest
        intraocular pressure will be selected for implant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roy Martin</last_name>
    <phone>763-670-5600</phone>
    <email>rmartin@microoptx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Derosier</last_name>
    <phone>612-638-7804</phone>
    <email>aderosier@microoptx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hanusch Krankenhaus - Sterngasse</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prof. Oliver Findl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Eye Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Burkhard Dick</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inga Kersten-Gomez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klink Nord</name>
      <address>
        <city>Hamburg</city>
        <zip>22417</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc Schargus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prof. Salvatore Grisanti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-University Mainz Langenbeckstr</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

